Malarivon

Chloroquine Phosphate, the active ingredient in Malarivon, is a 4‑aminoquinoline antimalarial presented as an oral dosage form for oral use. It treats malaria and is also employed in the management of certain autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus. GNH USA supplies Malarivon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarivon (chloroquine phosphate) is used in diseases where the parasite or immune modulation is targeted. - Malaria: effective for treatment and prophylaxis of infection caused by Plasmodium species. - Rheumatoid arthritis: reduces joint inflammation and disease activity in patients with moderate to severe disease. - Systemic lupus erythematosus: helps control cutaneous and systemic manifestations when other therapies are insufficient.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring early in treatment. - Headache: mild to moderate intensity, often transient. - Dizziness or vertigo: may affect balance, especially on standing. - Visual disturbances: blurred vision or photophobia, usually reversible.

Serious or Rare Side Effects: - Retinopathy: irreversible vision loss with prolonged use, requiring ophthalmologic monitoring. - Cardiac toxicity: arrhythmias or cardiomyopathy, particularly in patients with pre‑existing heart disease. - Severe hypoglycemia: unexpected low blood glucose, especially in diabetic patients on insulin or sulfonylureas.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Cardiac assessment: review history of QT prolongation or heart disease. - Blood glucose monitoring: patients with diabetes should have glucose levels checked regularly. - Renal or hepatic impairment: adjust dosing and observe for accumulation. - Hypersensitivity: discontinue if rash, pruritus, or anaphylaxis occurs. - Pregnancy: use only if clearly needed and after risk‑benefit discussion with a specialist. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Chloroquine phosphate can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, haloperidol): may precipitate life‑threatening arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase chloroquine plasma concentrations. - Antacids containing aluminum or magnesium: reduce absorption of chloroquine.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Insulin or oral hypoglycemics: risk of severe hypoglycemia, adjust dose as needed. - Rifampicin: induces metabolism, potentially lowering chloroquine efficacy.